PLUS1
7.62
-0.38 (-4.75%)
-0.38 (-4.75%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | VXRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.38 | -4.75% | 7.62 | 7.51 | 8.15 | 8.05 | 8.00 | 12:21:14 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 7.61 | 7.62 | 0.01 | 0.13% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 37,370 | 9,861,667 | $ 7.83 | $ 77,263,452 | 16,902,820 | 0.2543 - 14.30 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:21:16 | 7 | $ 7.615 | USD |
Vaxart Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 581.61M | 74.18M | 48.25M | $ 9.86M | $ - | -0.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Vaxart News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/30/2020 | 17:55 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/30/2020 | 17:25 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/17/2020 | 16:49 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/15/2020 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/09/2020 | 16:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/09/2020 | 16:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/09/2020 | 16:42 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.61 | 14.30 | 3.25 | 7.69 | 109,981,578 | 4.01 | 111.08% |
| 1 Month | 2.65 | 14.30 | 2.10 | 7.13 | 29,424,983 | 4.97 | 187.55% |
| 3 Months | 1.68 | 14.30 | 1.63 | 5.50 | 16,626,040 | 5.94 | 353.57% |
| 6 Months | 0.335 | 14.30 | 0.302 | 3.92 | 13,109,402 | 7.29 | 2,174.63% |
| 1 Year | 0.684 | 14.30 | 0.2543 | 3.80 | 6,894,669 | 6.94 | 1,014.04% |
| 3 Years | 7.70 | 14.30 | 0.2543 | 3.87 | 2,621,915 | -0.08 | -1.04% |
| 5 Years | 23.21 | 29.26 | 0.2543 | 4.08 | 1,611,024 | -15.59 | -67.17% |
Vaxart Description
| Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. |
